Legend Biotech Corp ADR (LEGN) concluded trading on Thursday at a closing price of $37.91, with 3.78 million shares of worth about $143.36 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.94% during that period and on June 12, 2025 the price saw a gain of about 3.61%. Currently the company’s common shares owned by public are about 184.03M shares, out of which, 181.38M shares are available for trading.
Stock saw a price change of 20.43% in past 5 days and over the past one month there was a price change of 21.98%. Year-to-date (YTD), LEGN shares are showing a performance of 16.50% which decreased to -16.75% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $27.34 but also hit the highest price of $60.87 during that period. The average intraday trading volume for Legend Biotech Corp ADR shares is 1.65 million. The stock is currently trading 22.80% above its 20-day simple moving average (SMA20), while that difference is up 18.76% for SMA50 and it goes to -1.72% lower than SMA200.
Legend Biotech Corp ADR (NASDAQ: LEGN) currently have 184.03M outstanding shares and institutions hold larger chunk of about 46.75% of that.
The stock has a current market capitalization of $6.98B and its 3Y-monthly beta is at 0.15. It has posted earnings per share of -$1.19 in the same period. It has Quick Ratio of 5.07 while making debt-to-equity ratio of 0.36. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LEGN, volatility over the week remained 4.74% while standing at 3.96% over the month.
Analysts are in expectations that Legend Biotech Corp ADR (LEGN) stock would likely to be making an EPS of -0.22 in the current quarter, while forecast for next quarter EPS is -0.11 and it is 0.63 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.24 which is -0.21 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.1 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 12.71% while it is estimated to increase by 243.24% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Redburn Atlantic on October 08, 2024 offering a Buy rating for the stock and assigned a target price of $86 to it. Coverage by Truist stated Legend Biotech Corp ADR (LEGN) stock as a Buy in their note to investors on June 17, 2024, suggesting a price target of $88 for the stock. On May 24, 2024, H.C. Wainwright Reiterated their recommendations, while on May 23, 2024, Deutsche Bank Initiated their ratings for the stock with a price target of $60. Stock get a Sector outperform rating from Scotiabank on April 17, 2024.
